“Comparative Efficacy of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Treatment Response in Atopic Dermatitis at Varying Treatment Continuance Rates”. 2025. SKIN The Journal of Cutaneous Medicine 9 (1): s519. https://doi.org/10.25251/skin.9.supp.519.